Introduction {#Sec1}
============

Type 2 diabetes is a disease that is increasing tremendously in prevalence worldwide, and is expected to more than double within the next 20 years and to affect 440 million people by 2030 \[[@CR1]\]. Formerly mostly found in adults and the elderly, the prevalence of type 2 diabetes is also increasing in children and adolescents \[[@CR2]\]. Effective and patient-orientated treatment is still a major task, since a large percentage of patients do not reach the therapeutic goal of a near normal HbA1c value as one criterion for an acceptable glycaemic control. Along with this dissatisfactory therapeutic effect, other important treatment goals, such as body weight reduction or the prevention of hypoglycaemic episodes, are not accomplished. Furthermore, type 2 diabetic patients have a significantly elevated cardiovascular mortality risk, which can be lowered by improved metabolic control \[[@CR3], [@CR4]\]. The established therapies are not able to halt the disease progression, which is caused by the continuous loss of function of the insulin-secreting beta cells in the islets of Langerhans. This loss of function is characterised by an increasing defect in the insulin response to glucose as well as a loss of beta cell mass over time. Furthermore, many established therapies are associated with an elevated incidence of hypoglycaemic events (sulphonylureas, glinides and insulin) or with an unwanted increase in body weight caused by the antidiabetic medications (sulphonylureas, glinides, glitazones and insulin) \[[@CR5]\].

In the past decade, the pharmacological actions of the incretin hormone glucagon-like peptide-1 (GLP-1) were utilised to develop two novel substance classes for type 2 diabetes therapy: the GLP-1 receptor agonists (or "GLP-1 mimetics") and the dipeptidyl-peptidase-IV inhibitors (DPP-4 inhibitors or "GLP-1 enhancers") \[[@CR6]\]. The incretin hormones GLP-1 and GIP (gastric inhibitory polypeptide, later often also referred to as glucose insulinotropic polypeptide) are secreted postprandially from the endocrine L- and K-cells in the intestinal mucosa respectively. Activation of promiscuous seven transmembrane receptors located in the intestinal wall and activated by nutrient components ("taste receptors") may additionally contribute to incretin secretion after a meal \[[@CR7]\]. These hormones are responsible for approximately 60% of the insulin secretion following a meal and for the so-called incretin effect. The incretin effect describes the phenomenon that oral glucose leads to a greater insulin response than an isoglycaemic intravenous glucose load \[[@CR8], [@CR9]\]. In patients with type 2 diabetes, the incretin effect is diminished. One important reason for this loss is that GIP does not act as an insulinotropic hormone under chronic hyperglycaemia in type 2 diabetes. GLP-1 on the other hand is still able to stimulate insulin secretion under hyperglycaemia in type 2 diabetes \[[@CR10]\]. Conversely, hyperglycaemia acutely reduces the postprandial levels of GIP and GLP-1, possibly through a deceleration of gastric emptying. Therefore, the reduced incretin levels in some patients with type 2 diabetes could be a consequence rather than a cause of type 2 diabetes \[[@CR11]\].

Increasing GLP-1 plasma concentrations to pharmacological levels by exogenous GLP-1 application leads to a normalisation of the incretin effect with an adequate insulin response under hyperglycaemic conditions \[[@CR12]\].

Physiological actions of GLP-1 {#Sec2}
==============================

GLP-1 is a product of the glucagon gene and is post-translationally cleaved from preproglucagon in the neuroendocrine L-cells of the intestinal mucosa and in the central nervous system. It binds to highly specific GLP-1 receptors that belong to the G-protein coupled receptors \[[@CR6]\]. GLP-1 shows numerous actions in different tissues and a broad therapeutic potential (see Fig. [1](#Fig1){ref-type="fig"} for details). Fig. 1Multiple physiological effects of GLP-1 (adapted with permission from \[[@CR6], [@CR104]\])

GLP-1 stimulates insulin secretion of the beta cells and additionally inhibits glucagon secretion from the alpha cells. Both actions occur in a glucose-dependent manner and lead to a normalisation of postprandial and fasting hyperglycaemia. GLP-1 furthermore slows gastric emptying. This effect also contributes to a normalisation of postprandial hyperglycaemia (see below). Under hypoglycaemic conditions the counter-regulation by glucagon is not affected and insulin secretion is not stimulated. GLP-1 is therefore not able to elicit hypoglycaemia by itself \[[@CR6]\].

Animal studies in rodents and studies in isolated human islets showed beneficial long-term actions of GLP-1: insulin synthesis is stimulated by GLP-1 and beta cell mass is increased \[[@CR6], [@CR13], [@CR14]\]. Whether these findings are relevant for long-term type 2 diabetes therapy with a positive effect on halting disease progression is not known, since long-term study data are still not available and beta cell mass cannot yet be quantified in humans in a clinical setting.

GLP-1 binds to its receptor on hypothalamic neurons and stimulates satiety. In the gastrointestinal tract, GLP-1 has a direct effect on motility and slows gastric emptying. These two effects explain that long-term treatment with GLP-1 receptor agonists lead to weight loss in the long run \[[@CR6]\].

Furthermore, pharmacological application of GLP-1 receptor agonists lead to an improvement in cardiovascular parameters (reduction of systolic blood pressure, beneficial effects on myocardial ischaemia in animal models, positive effects on left ventricular function in heart failure) \[[@CR15]--[@CR17]\].

GLP-1 is degraded rapidly by the ubiquitous enzyme dipeptidyl-peptidase IV (DPP-4). An animal study in rodents even showed that DPP-4 expression in the intestine and kidneys increased with high-fat feeding and type 2 diabetes \[[@CR18]\]. Intravenously administered GLP-1 has a biological half-time of approximately only 1--2 min \[[@CR6]\]. Also, subcutaneous injections of GLP-1 do not lead to a sufficiently high and long-lasting elevation of GLP-1 concentrations to use native GLP-1 as a practical therapeutic agent. An adenoviral vectored gene therapeutic option transfecting the GLP-1 gene into hepatozytes of a diabetic rat strain showed positive effects in one study, but because of the present difficulties and safety concerns using these methods in humans, this theoretical option has not been followed up so far \[[@CR19]\]. In order to utilise GLP-1 action for type 2 diabetes therapy, two options are presently available \[[@CR6]\]: GLP-1-receptor agonists (or GLP-1 mimetics) as injectable compoundsDipeptidyl-peptidase-IV (DPP-4) inhibitors (or incretin enhancers) as orally active substances

The following paragraphs deal with the approved compounds.

GLP-1 receptor-agonists, exenatide and liraglutide {#Sec3}
==================================================

Exenatide (Byetta®, Eli Lilly Pharmaceuticals) was the first GLP-1 receptor agonist to be approved for the treatment of type 2 diabetes in combination with metformin and/or a sulphonylurea in patients failing to reach the therapeutic goals with this oral medication \[[@CR20]\]. Exenatide is the synthetic form of exendin-4, a peptide first discovered in the saliva of the gila monster (heloderma suspectum) in 1992. It has a 53% amino acid sequence homology to human GLP-1 and is a strong GLP-1 receptor agonist \[[@CR21]\]. It is administered subcutaneously twice daily. A slow release formulation for once-weekly administration (Exenatide LAR \[long-acting release\]) is presently in clinical phase III studies \[[@CR22]--[@CR24]\]. The long-acting human GLP-1 analogue liraglutide (Victoza®, Novo Nordisk Pharmaceuticals) for once-daily dosing has just been approved by the European Medicines Agency (EMEA) \[[@CR25]--[@CR27]\]. Further compounds for once-daily or once-weekly application are in development (taspoglutide, Roche Pharmaceuticals \[[@CR28]\]; AVE0010, Sanofi-Aventis Pharmaceuticals \[[@CR29]\]; albiglutide, GlaxoSmithKline Pharmaceuticals \[[@CR30]\]).

Exenatide has a prolonged half-life in comparison to native GLP-1 of approximately 3.5 h. After subcutaneous injection sufficient plasma concentrations are reached for 4--6 hours \[[@CR20], [@CR31], [@CR32]\]. Exenatide lowered the HbA1c by 0.8--1.1% in clinical studies \[[@CR33]--[@CR35]\]. The reduction of HbA1c was constant over a time period of 3 years in one study \[[@CR16]\]. Comparative studies with insulin show that effects of exenatide on glycaemic parameters are comparable to the improvement seen with a newly started insulin therapy \[[@CR16], [@CR20], [@CR36]--[@CR39]\].

Patients receiving exenatide showed a significant drop in body weight by 1.5--3.0 kg after 30 weeks. The patients who continued to use exenatide lost further weight (5.3 kg after 3 years) \[[@CR16], [@CR40]\]. The comparative studies with insulin showed a difference in weight development of 4--5 kg in 30 weeks between the insulin- and exenatide-treated groups \[[@CR36], [@CR37], [@CR39]\].

An improvement of beta cell function (measured with the clinical surrogate parameters insulin secretion rate HOMA B (homeostatic modelling assessment of beta cell function) and the proinsulin:insulin ratio) was also observed in the clinical studies. Furthermore, the first phase of insulin secretion is restored after an intravenous glucose bolus under treatment with exenatide \[[@CR20], [@CR40]\]. However, in a 1-year study with exenatide and a consecutive wash-out phase of 12 weeks, the improvements in the above-mentioned beta cell function parameters were no longer present after the end of the wash-out period \[[@CR41]\].

Severe hypoglycaemic events were only observed in exenatide-treated patients who had received combination therapy with a sulphonylurea. In the comparative studies comparing exenatide with insulin treatment, the rates of hypoglycaemic episodes was similar in the patient group that had sulphonylurea--exenatide combination therapy. However, the incidence of nocturnal hypoglycaemic events was lower in the exenatide-treated patients \[[@CR20], [@CR40]\].

The most frequent adverse events were fullness and nausea. These were less pronounced when the exenatide dose was titrated from a small dose to the full dose at the beginning of treatment. Generally, nausea was mild to moderate occurring in the first weeks of treatment and ceasing with time. Nausea was the most common reason to stop therapy with 2--6.4% drop-outs in the clinical studies with exenatide \[[@CR16], [@CR20], [@CR40]\].

In approximately 40% of exenatide-treated patients, anti-exenatide antibodies can be detected. Over a time period of at least 3 years, these antibody titres did not have any obvious effect on glycaemic control. Furthermore, the exenatide antibodies do not cross-react with human GLP-1 \[[@CR24]\].

Since exenatide has been approved, cases of acute pancreatitis have been reported \[[@CR42], [@CR43]\]. The Food and Drugs Administration of the United States (FDA) in reaction then published a warning. In total, the incidence of pancreatitis is very low and rather corresponds to the elevated risk of pancreatitis in obese type 2 diabetic patients. Type 2 diabetic patients have an elevated pancreatitis risk due to a higher prevalence of gall stones, hypertriglyceridaemia and other factors, and a recent meta-analysis confirmed this \[[@CR44]\].

Exenatide is predominantly eliminated by glomerular filtration followed by proteolytic degradation \[[@CR45]\]. Its use is not recommended in patients with severe renal insufficiency (creatinine clearance \<30 ml/min). In patients with end-stage renal disease on dialysis, exenatide (5 µg) has been poorly tolerated because of gastrointestinal side effects \[[@CR20], [@CR40]\]. Just recently, the FDA published a warning after having observed 78 cases of altered renal function under exenatide therapy in the time period from 2005 to 2008. These cases comprised 62 patients with acute renal failure and 16 cases of renal insufficiency. Some cases occurred in patients with pre-existing kidney disease or in patients with one or more risk factors for developing kidney problems \[[@CR46]\]. These complications may have been associated with nausea, vomiting and consecutive dehydration and worsening of kidney function. According to the warning by the FDA, exenatide should not be used in patients with severe renal impairment (creatinine clearance \<30 ml/min) or end-stage renal disease. Additionally, caution should be applied when initiating or increasing doses of exenatide in patients with moderate renal impairment (creatinine clearance 30--50 ml/min). Patients should be carefully observed for the development of kidney dysfunction under therapy.

There is one published paediatric study that investigated the pharmacology and tolerability of a single dose of exenatide in 13 adolescents (aged 10--16 years) with type 2 diabetes and a baseline HbA1c of 8.2% on an ongoing stable therapy with metformin, a sulphonylurea or a combination of both. Pharmacokinetics and the safety profile of exenatide were the primary endpoints. The secondary endpoints comprised postprandial plasma glucose, serum insulin as well as plasma glucagon concentrations. The exenatide AUC (area under the curve) expectedly appeared to be dose-dependent. However, exenatide was not quantifiable in all patients at the lower 2.5- µg dose. Single doses of 2.5 µg and 5.0 µg of exenatide were well tolerated and normalised postprandial glucose and glucagon concentrations compared with placebo (*P* \< 0.01). Insulin plasma concentration did not differ significantly after exenatide and placebo. No hypoglycaemic events were recorded during the study \[[@CR47]\].

Liraglutide {#Sec4}
===========

Liraglutide is the first human GLP-1 analogue. It has two modifications in the amino acid sequence of native GLP-1 and an attachment of a fatty acid side chain to the peptide. It is injected subcutaneously once daily \[[@CR26]\].

In animal studies with diabetic rodents, liraglutide has been shown to increase beta cell mass. Liraglutide lowers blood glucose, body weight and food intake in a broad selection of animal models \[[@CR48]\]. In clinical studies in type 2 diabetic patients involving approximately 4,200 patients receiving the drug, it is efficacious and safe in the treatment of type 2 diabetes across all stages of the natural course of the disease \[[@CR25], [@CR49]--[@CR54]\].

In a clinical study using liraglutide in monotherapy in newly diagnosed type 2 diabetic patients it led to a sustained and stable HbA1c reduction of 0.9--1.1% in a dose of 1.2 or 1.8 mg once daily respectively, over a period of up to 2 years \[[@CR55], [@CR56]\].

In other studies, the same doses of liraglutide effectively lowered glycaemic parameters in various combinations with oral antidiabetic drugs by approximately 1.0--1.5%. Liraglutide treatment additionally led to a significant weight loss comparable to that previously observed in studies with exenatide \[[@CR57], [@CR58]\]. The weight loss was accompanied by a more pronounced loss in visceral fat than subcutaneous fat \[[@CR57]--[@CR59]\].

Furthermore, systolic blood pressure was lowered by 2--6 mmHg in the liraglutide-treated patients. This effect was independent of the weight loss, as the reduction of blood pressure was already observed early on in therapy, when weight loss had not yet occurred \[[@CR54]--[@CR56], [@CR59]\].

The incidence of hypoglycaemic episodes was comparable to placebo in all studies and study arms, where no sulphonylurea was used in the combination with liraglutide \[[@CR57], [@CR58]\]. Gastrointestinal symptoms were also common in clinical studies with liraglutide, but nausea and vomiting were less frequent and only reported for a shorter period at the beginning of therapy compared with exenatide \[[@CR60]\]. Antibody formation against liraglutide was only 8.6% in the clinical studies \[[@CR55]--[@CR58]\]. In a study directly comparing the clinical efficacy and safety of exenatide and liraglutide, liraglutide had an advantage with regard to lowering the glycaemic parameters HbA1c and fasting glucose and to improving HOMA-B \[[@CR60]\]. Liraglutide improves the first phase of insulin secretion after intravenous glucose as well as the insulin response to a maximal stimulation with arginine \[[@CR61]\].

Data on the pharmacokinetic profile of liraglutide in mild to moderate renal impairment show no alteration of the profile \[[@CR57], [@CR58]\]. So far, no studies of paediatric patients with type 2 diabetes and liraglutide therapy have been published.

DPP-4 inhibitors: sitagliptin, vildagliptin and saxagliptin {#Sec5}
===========================================================

DPP-4 inhibitors are orally active and tolerated well. After once- or twice-daily dosing they effectively inhibit DPP-4 and lead to a postprandial elevation of endogenous GLP-1 concentrations 2--3 times normal physiological levels \[[@CR62], [@CR63]\]. The presently available compounds are sitagliptin (Januvia®, Merck Pharmaceuticals), vildagliptin (Galvus®, Novartis Pharmaceuticals) and saxagliptin (Onglyza®, AstraZeneca and Bristol-Myers Squibb Pharmaceuticals) \[[@CR64]\]. They are approved in combination with metformin, a sulphonylurea or a glitazone or a combination of metformin and a sulphonylurea. Sitagliptin is also approved for monotherapy in the USA and in monotherapy for patients with metformin contraindications or intolerance in Europe \[[@CR62]\]. There are fixed-dose combinations for both sitagliptin and vildagliptin with metformin (sitagliptin plus metformin: Janumet®, Merck Pharmaceuticals, vildaglitpin plus metformin: Eucreas®, Novartis Pharmaceuticals). Further DPP-4 inhibitors are in clinical studies (alogliptin, Takeda Pharmaceuticals \[[@CR65]\]; linagliptin, Boehringer Ingelheim Pharmaceuticals \[[@CR66]\] and others) \[[@CR64]\].

Sitagliptin is the first DPP-4 inhibitor to be approved. In mono- as well as in combination therapy it lowers HbA1c by 0.6--1.1% compared with placebo in a standard dose of 100 mg once daily \[[@CR62], [@CR67]--[@CR69]\]. Likewise, it reduces fasting plasma glucose and postprandial glucose significantly. Sitagliptin was weight-neutral in all studies \[[@CR62], [@CR67]--[@CR69]\]. As an add-on to an existing metformin therapy, it was able to lower the HbA1c by 0.7%. In a primary combination therapy with metformin, a constant and sustained reduction of HbA1c and fasting plasma glucose was observed over a time period of 2 years \[[@CR70]\]. The incidence of hypoglycaemic episodes observed under sitagliptin was comparable to that under placebo \[[@CR69]\]. An improvement of the proinsulin:insulin ratio as a surrogate parameter of beta cell function was observed in clinical studies in sitagliptin-treated patients \[[@CR62], [@CR67], [@CR68], [@CR70]\]. The most common side effects of sitagliptin were unspecific, like headache, arthritis, nasopharyngitis, respiratory or urinary tract infections and rarely skin reactions \[[@CR69]\]. Adverse events concerning infections showed the largest difference compared with placebo and were more frequent in the sitagliptin-treated patients (sitagliptin 34.5%, placebo 32.9%; 95% confidence interval −0.8 to 4.0) \[[@CR71]\].

The elimination and excretion of sitagliptin is mainly renal (75% of an oral dose is found in the urine as unchanged drug); the elimination half-time is 12--14 h \[[@CR72]--[@CR74]\]. Sitagliptin was also generally well tolerated and effective in patients with impaired renal function. In this study, a dose of 25 mg/day was chosen for patients with a creatinine clearance of \<30 ml/min or end-stage renal disease, a dose of 50 mg/dl was given to patients with a creatinine clearance between 30 and 50 ml/min \[[@CR75], [@CR76]\].

Vildaglitpin is the second available compound of the DPP-4 inhibitors with approval in Europe and many other countries. Its dosage is 50 mg twice daily. In clinical studies testing vildaglitpin in monotherapy or combination therapy with metformin, glimepiride, pioglitazone or insulin, vildagliptin was able to decrease the HbA1c by approximately 0.5--1.0% \[[@CR62], [@CR67], [@CR68]\]. As an add-on therapy to metformin, it decreased the HbA1c by 0.65--1.1% \[[@CR77]\]. Vildagliptin has a good safety and tolerability profile and the most common adverse events are unspecific (flu-like symptoms, headache, dizziness, rarely liver enzyme elevations during the initiation of therapy). The incidence of hypoglycaemic episodes is also comparable to that of placebo. Vildagliptin, like the other DPP-4 inhibitors, is also weight-neutral. Study data with vildagliptin demonstrated a positive influence on acute and medium-term parameters for insulin secretion under vildagliptin treatment \[[@CR62], [@CR68], [@CR77]\]. In this respect, HOMA B improved as well as the proinsulin:insulin ratio and the first phase of insulin secretion after intravenous glucose \[[@CR78]\]. Vildagliptin has been tested in an elderly population, where it was shown to be efficacious and safe \[[@CR79]\].

Long-term studies investigating cardiovascular outcomes and a possible positive influence on disease progression of type 2 diabetes are being carried on with DPP-4 inhibitors.

Saxagliptin was subjected to a large phase III study program. A dose-range study showed a dose-dependent reduction in HbA1c by 0.7--0.9% (baseline HbA1c 7.9%). Fasting plasma glucose was also lowered dose-dependently \[[@CR80]\]. In a study with drug-naïve patients, saxagliptin lowered glycaemic parameters (HBA1c, fasting plasma glucose and postprandial glucose) significantly \[[@CR81]\]. As an add-on medication to a therapy with either metformin or a glitazone, saxagliptin also led to significant metabolic improvements comparable to other DPP-4 inhibitors \[[@CR64], [@CR82]--[@CR85]\]. Saxagliptin did not cause hypoglycaemia, was well-tolerated and was weight-neutral. A meta-analysis of the clinical phase III studies showed favourable data on the development of cardiovascular events \[[@CR86]\].

Common characteristics of and differences between incretin-based therapies {#Sec6}
==========================================================================

The incretin-based therapies offer a good alternative to the established antidiabetic compounds due to their satisfying antihyperglycaemic efficacy, their lack of risk of causing hypoglycaemia and their positive effects on body weight development. A further advantage is their positive effect on the insulin response of the beta cells. At this time, however, it is not yet clear, whether incretin-based therapies will lead to a sustained and durable positive effect on beta cell function and mass under clinical conditions in patients with type 2 diabetes. Animal data suggest that the novel compounds may lead to a retardation or halting of the progression of type 2 diabetes.

The most patient-relevant and striking difference between the incretin-based therapies is that GLP-1 receptor agonists are injectable agents, while DPP-4 inhibitors are effective orally (Table [1](#Tab1){ref-type="table"}). Glycaemic control seems to be improved more effectively by GLP-1 receptor agonists in comparison to DPP-4 inhibitors, but the data of a study directly comparing the efficacy and safety of liraglutide with sitagliptin are not yet available. Also, only GLP-1 receptor agonists lead to a reduction in body weight, whereas DPP-4 inhibitors are weight-neutral. Nausea, the most common adverse event observed with GLP-1 receptor agonist therapy is not observed in treatment with DPP-4 inhibitors. So far, no characteristic pattern of adverse events has been observed with the DPP-4 inhibitors. DPP-4 is also expressed on the plasma membrane of T-lymphocytes, where it was first described as a CD-26 receptor. However, no immunological alterations have been observed with DPP-4 inhibitor therapy. Furthermore, DPP-4 has multiple substrates (all peptides with a penultimate alanine or proline in the N-terminal position); the physiological effect of DPP-4 inhibition on all substrates has not been characterised in full detail as yet. Further long-term studies should clarify the long-term effects and safety of DPP-4 inhibitors. Table 1Differences between GLP-1 receptor agonists and DPP-4 inhibitorsProperties/actionGLP-1 receptor agonistsDPP-4 inhibitorsApplicationSubcutaneousOral"GLP-1" levelsPharmacological (\>5x)Physiological (2--3x)GLP-1 effectsInteraction with receptors on target organs (hormonal signal pathway)Interaction with receptors on afferent nerves (mixed neural/hormonal signal pathway)Duration of "GLP-1" elevationLong, continuouslyOn-off, postprandiallyOther mediatorsNoGIP, PACAP, othersEffect on gastric emptyingYesNone/scantyAppetiteReducedBarely influencedEffect on body weightWeight lossWeight-neutralAdverse eventsNausea/fullness\
Exenatide: antibodies (?)(Elevation of liver enzymes with vildagliptin in high doses?)*GIP* gastric inhibitory polypeptide, *PACAP* pituitary adenylate cyclase activating polypeptide

Indications for incretin-based therapies and their placement in treatment guidelines for type 2 diabetes {#Sec7}
========================================================================================================

The DPP-4 inhibitors sitagliptin, vildagliptin and saxagliptin are approved in many countries for an oral combination therapy, when therapeutic goals are not reached with life-style intervention and metformin monotherapy. The DPP-4 inhibitors play a role in this indication in the German guidelines and a recommendation by the British National Institute for Health and Clinical Excellence (NICE) for patients who should not be treated with sulphonylureas in order to prevent hypoglycaemia or further weight gain \[[@CR87], [@CR88]\]. A recent retrospective study has shown that a higher incidence of hypoglycaemia is associated with the development of symptoms of dementia \[[@CR89]\]. In this respect, hypoglycaemia avoidance as stated by NICE, is an important therapeutic goal. It should be noted that DPP-4 inhibitors lower the HbA1c by approximately 1.0% and that other treatment options (namely insulin) should be considered, if the HbA1c is elevated by more than 1.0% or if metabolic control has decompensated. The combination of metformin with DPP-4 inhibitors combined two synergistic treatment principles, metformin acting on insulin resistance and the DPP-4 inhibitor acting on the glucose-dependent stimulation of insulin secretion and inhibition of glucagon secretion (the same synergistic principle of action applies to the combination of a glitazone and a DPP-4 inhibitor). DPP-4 inhibitors are not inferior to sulphonylureas in the combination with metformin regarding glycaemic parameters \[[@CR90]\]. Theoretically, DPP-4 inhibitors may succeed sulphonylureas as insulinotropic agents, if the above-mentioned advantages are underlined by positive outcomes in long-term studies concerning glycaemic and other relevant endpoints as well as safety outcomes.

Therapy with a GLP-1 receptor agonist is a favourable treatment option when oral therapy with metformin or a combination therapy with metformin and a sulphonylurea are insufficient and a simultaneous loss of body weight is another therapeutic goal (e.g. obesity-associated complications and concomitant morbidity) or hypoglycaemia strictly has to be avoided (see above). Therapy with a GLP-1 receptor agonist at this stage may be a favourable alternative to initiating insulin treatment. If sulphonylureas are used before initiation of GLP-1 receptor agonist therapy, the sulphonylurea dose should be at least reduced when adding the GLP-1 receptor agonist. In a large proportion of patients, the sulphonylurea treatment can even be stopped.

Incretin-based therapies may help to bring a larger percentage of patients to their glycaemic goals. Fixed-dose combinations of a DPP-4 inhibitor with metformin may be a favourable alternative as the patient does not have to take more tablets when intensifying oral antidiabetic therapy with a DPP-4 inhibitor. Obese patients with weight loss as another important therapeutic goal may profit from therapy with a GLP-1 receptor agonist. The higher price of the novel incretin-based therapies is outweighed in some respects by the possibility of reducing the cost of blood glucose monitoring that is not necessary for safety reasons as long as the patient is not simultaneously treated with a sulphonylurea.

Prevention of hypoglycaemic events and prevention of further weight gain are important therapeutic goals considering the results of the ACCORD trial, which showed increased mortality in patients with type 2 diabetes who were allocated to the intensified treatment arm with an HbA1c goal \<6.0% and who were treated with multiple combinations of the classical antidiabetic agents \[[@CR91]\]. The increased mortality rate in this group may be explained by the higher gain in body weight and by the increased incidence of hypoglycaemic episodes. On the other hand, the 10-year follow up data of the UKPDS show that an early and effective diabetes treatment not only lowers microvascular complications, but also lowers macrovascular endpoints significantly \[[@CR4]\]. With respect to these study results, patients with a newly diagnosed type 2 diabetes should have a treatment that enables them to reach normoglycaemia in a safe way without the risk of hypoglycaemia or weight gain.

A consensus statement published in 2008 by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) separates the existing antidiabetic compounds and treatment algorithms into well-validated therapies ("tier 1", comprising metformin, sulphonylureas and insulin) and less well-validated therapies ("tier 2", comprising pioglitazone and GLP-1 receptor agonists). In this statement, the established substances are preferred according to their published endpoint and safety data as well as pharmaco-economic data. In the less well-validated therapies, GLP-1 receptor agonists, however, have their place as second therapeutic escalation after metformin failure in the same line as the widely used therapy with pioglitazone \[[@CR92]\]. In the German guidelines, DPP-4 inhibitors and GLP-1 receptor agonists are placed in second line after metformin failure, if the HbA1c does not exceed \>7.5% \[[@CR87]\].

Both incretin-based therapies may also play a role in the earlier or later stages of type 2 diabetes, when effectiveness is shown at these stages. Preliminary data show, that the addition of a DPP-4 inhibitor to existing insulin therapy further reduces HbA1c and may have a positive effect on hypoglycaemic events \[[@CR93], [@CR94]\]. Combination studies with insulin and GLP-1 receptor agonists are also being carried out and should bring results soon. Furthermore, long-term studies are underway, investigating the effect of incretin-based therapies on disease progression. Results of these studies are pending should be available by approximately the middle of the next decade. If these studies show an effect on disease progression, another argument in favour of using incretin-based therapies early in the disease will be supported by study data. Recently, animal and human studies showed a positive influence of GLP-1 or GLP-1 receptor agonists on the cardiovascular system and on the nervous system, describing neuroprotective effects \[[@CR17], [@CR95]--[@CR99]\]. These fields may also open novel indications for incretin-based therapies \[[@CR17]\]. However, long-term studies on hard cardiovascular endpoints and safety finally have to reveal important data in clarifying the efficacy, safety and placement of incretin-based therapies in type 2 diabetes therapy.

Incretin hormones, incretin-based therapy and renal failure {#Sec8}
===========================================================

GLP-1 has natriuretic actions that have been observed in several studies. These actions are in parallel to a diminished proton secretion. GLP-1 receptor activation most likely influences the activity of the sodium-proton exchanger 3 (NHE3 = natrium-proton \[H^+^\] exchanger 3) located in the brush border membrane of the proximal tubular cells by activation pathways involving cAMP (cyclic adenosine mono-phosphate) and protein kinase A \[[@CR100]\]. The GLP-1 receptor is expressed at the mRNA level and protein level in proximal tubular kidney cells \[[@CR101]\].

In an animal model of salt-sensitive obese db/db mice GLP-1 receptor activation by exendin-4 administration inhibited the development of hypertension. After a high salt load, urinary sodium excretion was delayed and hypertension was present in these animals. Exendin-4 was able to attenuate the latter effect. Exendin-4 also prevented angiotensin II-induced hypertension through the attenuation of angiotensin II-induced high-salt sensitivity \[[@CR102]\].

Changes in the secretion, in vivo degradation and elimination of the incretin hormones GLP-1 and GIP in patients with chronic renal insufficiency were characterised in a small study involving 10 patients with moderate renal failure (serum creatinine 2.18 ± 0.86 mg/dl) receiving an oral glucose tolerance test and GIP- and GLP-1 infusions on separate occasions. After an oral glucose load, plasma concentrations of intact GLP-1 and intact GIP are comparable in patients with renal insufficiency and healthy controls. The concentrations of the degradation products GIP \[[@CR3]--[@CR42]\] and GLP-1 (9--36 amide) are significantly higher in the patients than in the control subjects after oral glucose or after an exogenous infusion of either GIP or GLP-1. The insulin plasma concentrations were slightly lower in the patients during all experiments, whereas C-peptide levels tended to be increased. These data underline the importance of the kidneys for the final elimination of GIP and GLP-1. The initial DPP-4-mediated degradation of both hormones is almost unaffected by impairment of renal function. Delayed elimination of GLP-1 and GIP in renal insufficiency may influence the pharmacokinetics and pharmacodynamics of DPP-4-resistant incretin derivatives to be used for the treatment of patients with type 2 diabetes \[[@CR103]\].

Incretin-based therapies and type 1 diabetes {#Sec9}
============================================

Since GLP-1 has a positive effect on beta cell mass in rodents as well as a beneficial effect on the survival of isolated human islets in cell culture \[[@CR6], [@CR104], [@CR105]\], it is imaginable that incretin-based therapies may also be advantageous in type 1 diabetes, possibly in combination with immune therapy. First preclinical studies suggest that theoretically such a combination therapy may be feasible in the future \[[@CR106]\]. Besides the positive effect on the beta cells, GLP-1 may also influence glycaemic parameters in a favourable way by slowing gastric emptying and affecting glucagon secretion in type 1 diabetes \[[@CR107]\]. A small mechanistic study in type 1 diabetic individuals showed that an intravenous GLP-1 infusion reduced fasting hyperglycemia in the morning, which was provoked by omitting the basal insulin injection at night \[[@CR108]\]. Preclinical and animal studies should be undertaken to clarify the potential influence of GLP-1 on beta cell mass in type 1 diabetes and on possible alterations of the autoimmune process. Clinical studies could then be implemented to investigate the metabolic effects of incretin-based therapies in type 1 diabetes, provided there are no unwanted side effects on immune function in the preclinical studies.
